S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
Log in

NASDAQ:LPTXLeap Therapeutics Stock Price, Forecast & News

$2.08
-0.04 (-1.89 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.00
Now: $2.08
$2.10
50-Day Range
$1.77
MA: $2.09
$2.53
52-Week Range
$0.57
Now: $2.08
$3.18
Volume659,711 shs
Average Volume779,266 shs
Market Capitalization$116.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Read More
Leap Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.95 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.07) per share

Profitability

Net Income$-32,900,000.00

Miscellaneous

Employees23
Market Cap$116.58 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable
$2.08
-0.04 (-1.89 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

How has Leap Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LPTX shares have increased by 3.5% and is now trading at $2.08.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Leap Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Leap Therapeutics
.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Leap Therapeutics
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.31. The company had revenue of $0.38 million for the quarter.
View Leap Therapeutics' earnings history
.

What price target have analysts set for LPTX?

5 equities research analysts have issued 1-year target prices for Leap Therapeutics' stock. Their forecasts range from $2.50 to $8.00. On average, they anticipate Leap Therapeutics' share price to reach $5.50 in the next year. This suggests a possible upside of 164.4% from the stock's current price.
View analysts' price targets for Leap Therapeutics
.

Has Leap Therapeutics been receiving favorable news coverage?

Headlines about LPTX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Leap Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
View the latest news about Leap Therapeutics
.

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Amarin (AMRN), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Verastem (VSTM), Clearside Biomedical (CLSD), Genocea Biosciences (GNCA) and ImmunoGen (IMGN).

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Personal CFO Solutions LLC (0.13%). Company insiders that own Leap Therapeutics stock include Christopher Mirabelli and Perceptive Advisors Llc.
View institutional ownership trends for Leap Therapeutics
.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was bought by a variety of institutional investors in the last quarter, including Personal CFO Solutions LLC. Company insiders that have bought Leap Therapeutics stock in the last two years include Christopher Mirabelli, and Perceptive Advisors Llc.
View insider buying and selling activity for Leap Therapeutics
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $2.08.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $116.58 million. The company earns $-32,900,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is www.leaptx.com.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.